Glycan synthesis refers to the biochemical and chemo-enzymatic processes by which carbohydrate chains are assembled (in vivo or in vitro) to generate free oligo- or polysaccharides, as well as glycoconjugates. This process is a spatially orchestrated sequence of events rather than a single reaction. Glycan synthesis is primed by cytosolic monosaccharide activation to sugar-nucleotide donors, their vectorial transport into the endoplasmic reticulum and Golgi, and stepwise, enzyme-mediated transfer to an acceptor. Absence of a template for glycan assembly implies that the final pattern is the result of the relative activities of dozens of glycosyltransferases, glycosidases, and sulfo- or sialyl-transferases which cooperate or compete in dynamic vesicular flow. Branched structures that are occasionally sulfated or phosphorylated encode information that modulates protein folding, receptor clustering, immune evasion or microbial adhesion. The sequence, linkage and spatial orientation of each "letter" (monosaccharide) generates a specific meaning, but the same letter changes meaning in context.
Glycans are the most abundant, structurally diverse, and least genetically encoded class of biopolymers. Freely or covalently attached to proteins and lipids, glycans form a viscous hydrated meshwork that coats every living cell, known as the glycocalyx. In this meshwork, glycans are the primary point of contact between a cell and its environment: they mediate identity through blood-group antigens, regulate leukocyte trafficking during inflammation, and serve as attachment factors for viruses, bacteria and toxins. Glycan biosynthesis is energetically expensive and represents a nontrivial fraction of the cell's energy budget, consistent with an evolutionary pressure towards a diversity of carbohydrates. As a consequence, perturbations of glycan homeostasis are associated with congenital disorders, cancer and pathogen virulence. They are thus both a promising and technically challenging therapeutic target.
Fig.1 N- and O-glycan differ in their core structure.1,5
Glycans are linear or branched polymers of monosaccharides linked by glycosidic bonds. These links can differ in anomericity, linkage position, and ring conformation. Diverging from nucleic acids and proteins, glycan synthesis is not templated but rather directed by the spatial expression and catalytic specificity of glycosyltransferases and glycosidases. This enzymatic plasticity has permitted a small pool of building blocks to give rise to an astronomical number of structures. Functionally, glycans can be physicochemical buffers that stabilize proteins against proteolysis and thermal stress, mechanical dampers that bestow compressibility on cartilage, or cryptographic barcodes that distinguish self from non-self. Glycans can tune receptor tyrosine kinase signalling through clustering of ligands on the cell surface, directly prune synapses in the nervous system, and dictate the half-life of circulating hormones through recognition by carbohydrate specific receptors in the liver and spleen.
Endogenous glycans are assembled in the crowded lumen of the secretory pathway under kinetic (rather than thermodynamic) control. As a consequence, endogenous glycans are microheterogeneous: a single glycosylation site on a purified glycoprotein can support dozens of glycoforms that differ in only one or two monosaccharide. This variation is typically biologically useful: at the population level it can provide robustness to an evolving pathogen and a shifting metabolic milieu. But it complicates mechanistic studies: the structure–activity relationships of a glycan are smeared out by ensemble averaging. Researchers create synthetic glycans through chemical glycosylation reactions or by stopping engineered enzyme cascades at predetermined stages to generate monodisperse products. This permits unambiguous determination of single-residue contributions to protein folding stability, receptor binding affinity or immunogenicity, for example. Synthetic glycans may have incorrect or absent flexibility or have different hydrophobicity without their native protein and/or lipid context, although in some cases they may produce false-negative or false-positive biological signals. Glycans with unusual post-glycosynthetic modifications that synthetic versions lack, such as sialic acid O-acetylation or site-specific sulfation, can hide synthetic glycans from lectins or antibodies designed to detect rare natural glycoconjugate epitopes. Despite synthetic glycans serving as valuable tools for mechanism exploration and vaccine development their functionality needs consistent comparison with nature's diverse glycan structures.
Signal transduction also depends on the rapid conversion of extracellular signals into intracellular programs, a process enabled by the spatiotemporal regulation of receptor orientation, clustering and endocytosis, in many cases directed by glycans. The sialylated glycoproteins of host cells bind to inhibitory receptors termed Siglecs, which temper innate immune activation and prevent accidental self-reactivity. To take advantage of this inhibitory program, pathogens adorn their surface with sialic acid mimics to masquerade as "self". In contrast, exposure of terminal galactose or mannose residues, which is more often the result of apoptosis or microbial infection, serves as an "eat-me" signal for lectin receptors on macrophages and dendritic cells to facilitate phagocytosis. Glycans can also provide the scaffolding architecture necessary for clustering of lipid rafts to recruit T-cell receptors, co-receptors and downstream kinases and thereby reduce the threshold for T-cell activation. In a similar fashion, N-glycans on the Fc region of antibodies can also alter complement fixation and Fcγ receptor binding, thereby fine-tuning antibody effector functions such as antibody-dependent cellular cytotoxicity. Clearance of cytokines can also be regulated by glycans: The sialylated N-glycans that decorate IL-2 shield it from hepatic clearance whereas IL-2 mutants that lack this glycosylation undergo swift removal from circulation. Germinal center reactions can also be glycan-gated, as mannose-binding lectin can opsonize immune complexes and directly impact B-cell selection. Taken together, these instances demonstrate that glycans have active and multilayered roles in every aspect of immune surveillance from danger sensing to termination of inflammation and formation of memory.
De-novo glycan construction may follow one of two largely (but no longer strictly) philosophical paths – chemical or enzymatic – that differ in how the central glycosidic linkage is formed. Chemical synthesis regards the monosaccharide as a small organic molecule whose hydroxyl groups need to be temporarily protected, activated and deprotected in a strictly choreographed sequence. Enzymatic synthesis, on the other hand, outsources this bond-forming to a glycosyltransferase or glycosidase that is designed to interact with the bare, unprotected surface of the sugar. The former approach has no structural limits but requires heroic protecting-group gymnastics; the latter offers a water-compatible, stereocontrolled elegance but will not accept any substrate that it has not met in nature. Hybrid or "chemo-enzymatic" strategies have emerged as a pragmatic approach that speak both languages, installing non-natural fragments by chemical methods and elaborating them by enzymatic conversion. Fluency in both complementary toolkits now underlies the entire modern carbohydrate endeavor, from understanding innate immunity to programming next-generation glycomedicines.
The majority of chemical glycan synthesis follows the logic of protecting all hydroxyls except the one that should couple, then activating the anomeric center without harming the rest of the molecule. Benzyl ethers are stable to hydrogenolysis, and are thus universally used for permanent protection, whereas esters or carbonates are used as temporary protecting groups which can be removed orthogonally. The glycosylation event can be initiated by a wide range of leaving groups from trichloroacetimidates to thioglycosides. Each strategy has a favoured promoter strategy: Lewis acids, electrophilic halogen sources or photolatent bases. Since every coupling event creates a new stereogenic center, the polarity of the solvent, temperature ramp, and protecting-group pattern must be choreographed in concert to skew the reaction towards the desired α- or β-linkage. Solid-phase variants of this strategy have been imported from peptide chemistry: the first monosaccharide is attached through a photolabile or olefin-cleavable linker to a polystyrene bead, and excess donor is then driven through the resin repeatedly by cycling the reaction until coupling is deemed complete by colorimetric tests. Once the chain is complete, global deprotection releases the oligosaccharide into solution, where it can be conjugated or microarray printed. The intellectual elegance of this approach is its modularity: the same resin, the same capping steps, and the same washing protocol can be scripted into an automated loop that runs overnight. But this method is not without its limits: sterically congested targets may still require a return to solution-phase fragment condensation, in which convergently prepared blocks are joined in a late-stage coupling that minimizes exposure of the most acid-labile motifs.
Enzymatic glycosylation utilizes the regio- and stereoselectivity of glycosyltransferases, which has evolved to near-perfection in a membrane-bound Golgi network. Outside of cells, they can be released from their lipid environment, solubilized, and supplied with sugar-nucleotide donors (UDP-GlcNAc, GDP-Fuc, CMP-Neu5Ac) produced on-demand by cheap cofactor regeneration systems, thus preventing the accumulation of inhibitory nucleoside diphosphates. Since the acceptor hydroxyl is constrained in the active site by an oriented hydrogen-bond network, only one linkage is formed, even in the presence of multiple competing nucleophiles, so no protecting groups are needed. Glycosidases, enzymes that typically hydrolyze glycosidic bonds, can be mutated at the catalytic nucleophile to produce glycosynthases, which use activated sugar fluorides as donor and catalyze transglycosylation without hydrolysis. Transglycosidases, in turn, can be used to shuffle sugars internally, snipping a high-mannose precursor and reattaching the released oligosaccharide fragment to a different acceptor (internally "grafted"). Multi-enzyme cascades can be co-localized inside permeabilized cells or immobilized on agarose beads to create flow-bioreactors that transform simple disaccharides directly to human milk oligosaccharides or tumor-associated antiglycans without isolation of intermediates. Of course, many transferases are strictly metal-dependent, some only work on lipid-linked acceptors, and very few will tolerate non-natural sugars, even if they differ by only one stereochemical center from the natural compound. Still, the recent boom in genome mining has yielded hundreds of putative enzymes from extremophiles and symbiotic microbes, vastly increasing the number of potential reactions.
Chemo-enzymatic synthesis has grown out of the recognition that chemistry and enzymes are respectively good at making novel and elongating existing glycosidic linkages, respectively. Synthetic cores, usually made by protecting-group chemistry that is not taken to completion, are turned over to a set of recombinant glycosyltransferases for elaboration with galactose, fucose, sialic acid, or other monosaccharides in a defined order, each enzyme in the cascade recognizing only the new terminal motif and being unable to "look back" over an extended chain. Since all of the enzymatic steps are performed in water, the initial chemical core must be designed to be both water-soluble and pH-stable to the mildly basic conditions needed to stabilize the donor nucleotides; in addition, hydrophobic protecting groups remaining on the chemical core after its synthesis must be removed before enzymatic processing so as not to micellize and sequester the acceptor substrate. Cascades in which CMP-Neu5Ac is regenerated in situ from the inexpensive starting materials Neu5Ac and CTP, while a parallel chemical reaction sulfates a remote galactose residue, have been constructed to work in one-pot. More complex schemes make use of stop-flow microreactors, using a T-junction for the chemical step to be performed in an organic solvent plug that is passed through a water-immiscible enzyme channel with the phases separated at a hydrophobic membrane and each biocatalyst thus being exposed only to its preferred solvent. Non-natural chemical handles (alkynes, diazirines, photolabile ethers, etc.) can be incorporated in the initial synthetic core and activated at a later stage for click-ligation to proteins, lipids, or surfaces, a manipulation that would not be possible if the entire glycan were constructed enzymatically. On the other hand, enzymatic remodeling can be used to "correct" the anomeric configuration of chemically synthesized glycans that contain undesired stereoisomers; an exo-glycosidase trims the anomeric linkage and a transferase rebuilds the correct motif, thus effectively proof-reading the chemical synthesis step. These iterative procedures are beginning to blur the historical distinction between synthetic organic chemistry and biocatalysis, leading to glycoconjugates that are neither entirely natural nor entirely synthetic but in some respects superior to both.
The overall process of glycan assembly can be summarized into three essential steps which repeat regardless of whether the synthesis is fully chemical, fully enzymatic, or a hybrid approach. The monosaccharide building block must be converted from a resting hemiacetal into an activated donor in which the anomeric leaving group is both electronegative enough to leave upon mild solicitation, and stable enough to remain intact upon handling. Second, the resulting oxocarbenium mimic must be trapped by a nucleophilic hydroxyl in a manner that is completely regio- and stereo-controlled, which requires all other alcohols on both coupling partners to be temporarily masked. Third, the protecting group camouflage that facilitated the selective coupling must be removed without "marking" the newly formed glycosidic linkage or oxidizing any functionality that may have been added in subsequent elaboration steps. Since each of these steps is reversible, the chemist must carefully tune the kinetics, solvent polarity, and counter-ion identity to ensure that the forward process is favored over the backward process. Success is not measured in brute force yields but rather in how well activation, coupling, and unmasking are integrated so that isolation of intermediates is optional and scale-up is only a matter of flux rather than flask size.
Activation starts by interrogating the anomeric centre itself: the ring oxygen can be coerced into opening under Lewis acidic conditions to form an oxocarbenium whose persistence is attenuated by the counter-ion's nucleophilicity. Traditional halide donors were designed with heavy-metal salts to produce glycosyl bromides or chlorides that are sufficiently stable to crystallize but reactive enough to couple under silver or mercury promotion, but toxicological issues have driven a search for softer leaving groups. Trichloroacetimidates are prepared by the base-mediated addition of trichloroacetonitrile to the anomeric hydroxyl, creating a donor that can be stored indefinitely at low temperature and activated at will by catalytic Bornsted acids whose pKa can be varied over several orders of magnitude. Thioglycosides, made by treatment of the anomeric acetate with a thiol under boron trifluoride catalysis, offer an orthogonal reactivity window: they are robust enough to survive protecting-group manipulations but then give way to electrophilic iodonium or sulfonium reagents at the moment of coupling. Phosphates and phosphoramidates extend this paradigm to aqueous environments, where leaving-group departure can be accelerated by metal chelation, making them amenable to late-stage enzymatic elaboration. The donor's protecting-group cloak must be pre-ordained: benzyl ethers stabilize the oxocarbenium through π-stacking, biasing the reaction towards β-linkages, whereas acyl esters react through neighbouring-group attack to freeze in 1,2-trans geometry. Rare sugars without commercial sources can be activated in situ by transient protection and anomeric oxidation followed by reductive exchange, thereby avoiding the isolation of unstable intermediates. Donor selection is therefore less a single decision than a strategic choreography of leaving-group electronics, protecting-group choreography and expected coupling milieu.
To forge the glycosidic tether, the required transient carbocation or surrogate must be channeled to one of many possible reaction channels. Solid promoters such as silver silicates or montmorillonite clays act by adsorbing both donor and acceptor on their surfaces, pre-organizing the nucleophile for back-side attack, while the heterogeneous environment shortens the lifetime of the oxocarbenium. In homogeneous catalysis, boron trifluoride etherate or trimethylsilyl triflate work by ion-pair separation to form a solvent-protected carbocation whose facial selectivity is determined by the steric mapping of the acceptor's approach vector. Temperature ramping takes advantage of the different enthalpies of competing reaction pathways: coupling at low temperature gives the kinetic α-product, which can, upon gentle warming, invert to the thermodynamic β-anomer by in situ anomerization. Solvent choice also has an electronic effect: ethereal solvents stabilize hydrogen-bonding networks that maintain the conformation of the acceptor, while nitrile solvents coordinate to the oxocarbenium, shortening its lifetime and minimizing competing elimination side reactions. Intramolecular delivery of the aglycon is a related strategy in which the acceptor is temporarily tethered to the donor by a silicon or ketal bridge, forcing the glycosylation to take an internal path that overrides conventional steric preferences. Photochemical activation, in its infancy, uses excited-state electron donors to form glycosyl radicals whose recombination with acceptor alkoxyls takes place with inverted spin selectivity, providing a mechanistic sidestep that avoids the classical ionic channels. Each method must be balanced against the downstream protecting-group schedule; a promoter that will not be removed after coupling can derail an entire synthesis, so recyclability and benign by-products are as important as stereocontrol itself.
Each hydroxyl group must be protected as a temporary governor that suppresses all of the others but the one designated for reaction. A challenge is that the protecting group must be removed after it has served its purpose, without disturbing other features of the molecule. In this regard, benzyl ethers, which can be installed by base-promoted Williamson coupling, are stable to the strongly acidic conditions used in glycosylation but are removed by hydrogenolytic cleavage in the presence of palladium on carbon or other palladium "dummy" catalysts that are absorbed onto a carbon support. Palladium on carbon, however, will also cause unexpected premature reduction of an alkene or azide that may be present for later conjugation. Acetyl or benzoyl esters can be installed using an acyl anhydride and, unlike benzyl ethers, they give neighboring-group participation during coupling and ensure 1,2-trans stereochemistry. The downside to these esters is that they are labile under basic conditions and may cause β-elimination of the aglycon moiety if the anomeric center is not protected. Silyl ethers have orthogonal lability, as triethylsilyl groups are cleaved under mildly acidic buffer conditions, while the more robust tert-butyldimethylsilyl ether requires a fluoride source that must be quenched as soon as possible to avoid formation of the glycosyl fluoride. Levulinate esters, which can be cleaved by hydrazine at near-neutral pH, can be used for late-stage deprotection of a single hydroxyl in a mixture of acetates to enable the repetitive one-block-at-a-time synthesis without global deprotection. Photolabile protecting groups, which have received relatively little attention, can be removed using near-UV light delivered through micro-masks to spatially pattern glycans without the need for wet chemistry. Enzymatic methods can be used to avoid many of these problems. For example, the anomeric center may still need to be temporarily masked, as unprotected reducing ends tend to hydrolyze instead. Allyl or propargyl groups can be used, and later cleaved using palladium or ruthenium catalysts in aqueous solution that can be compatible with co-incubation with proteins.
Synthetic glycans have become standardized molecular reagents that provide structural homogeneity and chemically defined functionality, rather than the structural heterogeneity that is typically found in natural isolates. As such, synthetic glycans provide synthetic chemists and biologists with the chemical control that was once only available for oligonucleotides and peptides. The ability to reproduce defined carbohydrate epitopes in milligram to gram quantities has now enabled researchers to study immune recognition events at the molecular level, create standardized calibrants for diagnostic testing, and design and produce glycoprotein surrogates that can be made biologically active and are also readily amenable to site-specific chemical modification. Further, the orthogonal installation of non-natural tags, isotopic labels, and photocrosslinkers have broadened the use of synthetic glycans into imaging, single-molecule force spectroscopy, and affinity-proteomics applications. Synthetic glycans are therefore the common denominator that links vaccine design, early stage disease detection, and mechanistic glycoproteomics.
Synthetic chemistry has disrupted the paradigms of vaccine discovery. By shifting away from antigenic identity being tied to microbial fermentation, and towards a chemically-defined glycan sequence, problems of batch-to-batch drift, endotoxin contamination, and sub-chronic carrier protein suppression can be avoided. In place of growing and lysing the pathogen and purifying the capsular polysaccharide, a single repeating unit or a minimal helical fragment can be constructed that mimics the protected immunodominant epitope recognized by human sera. Conjugated to genetically detoxified carrier proteins using chemoselective linkers that position the carbohydrate at a distance from the immunodominant peptide epitopes, the resulting neoglycoconjugates can be used to prime an immune response that is polyclonal in nature. The specificity of which can then be interrogated on glycan microarrays to determine the hydroxyl, sialic acid, or sulfate that is the contact residue. Further trimming or extending of the oligosaccharide then yields a length-activity curve to inform lead selection without the need for animal studies beyond proof-of-concept. Antibodies from such a homogeneous target are likely to have a more constrained paratope diversity and be more amenable to humanization. Furthermore, knowing the structure can be used to inform structure-guided affinity maturation that locks the complementarity-determining loops onto the target saccharide. Synthetic glycans can also be appended with photocleavable or click-compatible handles that allow for irreversible capture of the primed B-cell receptor and acceleration of single-cell sequencing campaigns that generate recombinant antibodies in weeks rather than months. Finally, by having the exact same glycan scaffold be synthetically resynthesizable years later, a reference standard is provided to regulatory agencies that cannot suffer from microbial evolution, ensuring consistency of clinical trial materials across multi-site clinical trials and post-market surveillance of breakthrough infections due to serotype replacement.
Fig. 2 Chemo-enzymatic approach to prepare homogeneous antibodies.2,5
The utility of glycans as biomarkers stems from their ability to report on pathophysiological conditions ignored by proteins or nucleic acids; for example, malignant transformation often results in the truncation of O-glycan cores or the hypersialylation of N-glycan antennae long before mutations are detectable at appreciable allele frequency. Synthetic glycans offer calibrants and capture reagents that can convert these early and subtle changes into clinically actionable signals. On planar microarrays, hundreds of sequence-defined oligosaccharides are covalently anchored at a consistent surface density, and a single droplet of patient serum can be interrogated for the entire repertoire of anti-glycan antibodies in minutes. The same microarray can be reconstituted into a bead-based suspension, where each glycan is read out by a unique fluorescence signature, allowing multiplexed flow-cytometric measurements compatible with off-the-shelf hematology analyzers. In addition to serology, glycan-coated nanoparticles have also been used as synthetic lectins: gold cores functionalized with LacNAc dimers form aggregates in the presence of fucosyltransferase activity, leading to a visible colorimetric readout that reports on oncogenic fucosylation in real time. Alternatively, magnetic nanoclusters decorated with sulfated Lewis antigens can be used to enrich circulating tumor cells from whole blood, providing a liquid-biopsy sample for downstream glycoproteomic interrogation. Mass-spectrometric quantitation of enzymatically released glycans is also dependent on isotopically labeled synthetic standards that account for ion-suppression effects, so that any apparent changes in sialylation can be confidently attributed to biology rather than instrument drift. Perhaps most transformative are electrochemical biosensors in which synthetic glycans are directly wired to conductive polymers; binding of viral hemagglutinins or bacterial adhesins changes the redox potential in a concentration-dependent manner, leading to smartphone-readable currents within seconds—an attribute particularly well-suited to low-resource environments without PCR infrastructure.
Ideally, glycoproteomics aims to achieve site-specific coverage of the glycan landscape. However, in natural samples, the biological target itself is often a moving one made up of hundreds of glycoforms for every peptide of interest. Synthetic glycopeptides with one defined glycan attached at a known engineered site on asparagine or serine residues can be used as "ground truth" standards where retention time and fragmentation signatures are catalogued in searchable libraries. Isotopically heavy analogs of such surrogates can be spiked into complex digests to enable precise quantitation of disease-associated changes without relying on label-free algorithms that are confounded by glycopeptide microheterogeneity. Cross-linkable glycans also open up spatial glycoproteomics of multi-subunit complexes: a photoreactive aryl azide on the reducing end of an N-glycan will covalently tag lectins or antibodies in close proximity (within nanometers) of the glycosylation site to yield a picture of the native glycan–protein microenvironment, for example, that cannot be perturbed by detergent lysis. Chemically synthesized glycosylphosphatidylinositol (GPI) anchors with authentic inositol acylation and lipid heterogeneity have restored anchoring of prion protein in model membranes to show that lipid raft partitioning is controlled by the GPI fatty acyl chain length and saturation. "Clickable" O-GlcNAc peptides on the other hand that feature terminal alkynes allow time-resolved measurements of cycling on nuclear pore proteins to show that O-GlcNAc turnover occurs on the minute timescale of extracellular glucose changes, something which could not have been discovered using genetic tools alone. Finally, synthetic glycopeptides that feature non-canonical sulfation or phosphorylation can be used as activity-based probes to discover and profile sulfo- and kinases that modify glycans in cis, independent of the canonical glycosyltransferase complement.
Understanding how glycans are synthesized is only the first step—turning that knowledge into actionable research outcomes requires precision, experience, and advanced technology. Our professional glycan synthesis services provide end-to-end support for academic and biopharma teams looking to design, synthesize, and characterize complex carbohydrate structures with confidence.
Every project begins with a clear molecular blueprint. Our experts collaborate with you to define structural goals, choose optimal monosaccharide building blocks, and determine the most effective chemical or enzymatic synthesis route for your research application. Whether you need a simple disaccharide or a highly branched glycan library, we tailor every synthesis to your specifications.
Using state-of-the-art synthesis platforms—including automated glycan assembly (AGA) and solid-phase carbohydrate synthesis—we ensure reproducible results and high yield. Each glycan is rigorously purified and validated through HPLC, LC-MS, and NMR to guarantee accuracy, structural integrity, and biocompatibility.
Our services go beyond synthesis. We combine glycan profiling and structural analysis to verify linkage positions, monosaccharide composition, and functional performance. This integrated approach reduces turnaround time and ensures data consistency across your workflow.
Whether you're scaling up production or conducting early-stage discovery, our custom glycan synthesis solutions deliver both scientific precision and commercial reliability. Join leading biotech innovators who trust us to accelerate their glycoscience programs.
Ready to start your project? Contact our Glycan Synthesis Team to request a consultation or a customized quotation today.
1. What is glycan synthesis in simple terms?
Glycan synthesis is the chemical or enzymatic construction of carbohydrate structures called glycans. These molecules play key roles in cell communication, protein stability, and immune response.
2. Why are synthetic glycans important in research?
Synthetic glycans allow scientists to precisely control molecular structure for studies in immunology, oncology, and vaccine design—something not always possible with natural sources.
3. What methods are used for glycan synthesis?
Two main approaches are used: chemical synthesis, which builds glycans step by step, and enzymatic synthesis, which uses glycosyltransferases for selective bond formation.
References
